Sangamo BioSciences PT Raised to $22.00 at Wedbush (SGMO)
Analysts at Wedbush increased their target price on shares of Sangamo BioSciences (NASDAQ:SGMO) to $22.00 in a research report issued to clients and investors on Thursday, Analyst Ratings Net reports. Wedbush’s price objective would indicate a potential upside of 61.17% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Lazard Capital Markets raised their price target on shares of Sangamo BioSciences from $16.00 to $20.00 in a research note to investors on Wednesday, October 23rd. They now have a “buy” rating on the stock. Analysts at Thomson Reuters/Verus upgraded shares of Sangamo BioSciences from a “sell” rating to a “hold” rating in a research note to investors on Monday, October 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $18.75.
Shares of Sangamo BioSciences (NASDAQ:SGMO) traded up 34.36% during mid-day trading on Thursday, hitting $18.34. The stock had a trading volume of 8,981,745 shares. Sangamo BioSciences has a 52 week low of $6.75 and a 52 week high of $14.60. The stock has a 50-day moving average of $12.71 and a 200-day moving average of $10.70. The company’s market cap is $1.133 billion.
Sangamo BioSciences (NASDAQ:SGMO) last posted its quarterly earnings results on Wednesday, October 23rd. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). The company had revenue of $5.70 million for the quarter, compared to the consensus estimate of $5.52 million. During the same quarter last year, the company posted ($0.11) earnings per share. Sangamo BioSciences’s revenue was up 16.3% compared to the same quarter last year. On average, analysts predict that Sangamo BioSciences will post $-0.44 earnings per share for the current fiscal year.
In other Sangamo BioSciences news, VP Philip Gregory sold 15,000 shares of Sangamo BioSciences stock on the open market in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $13.56, for a total value of $203,400.00. Following the completion of the sale, the vice president now directly owns 109,347 shares of the company’s stock, valued at approximately $1,482,745. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Sangamo BioSciences, Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (NASDAQ:SGMO)-binding proteins (ZFPs), a naturally occurring class of proteins.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.